Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease

Brain Research Reviews
Naoyuki NakaoToru Itakura

Abstract

Grafting of catecholamine-producing cells can be a possible therapeutic strategy for attenuating motor symptoms in Parkinson's disease (PD). The potential of autologous sympathetic neurons has been investigated as a donor for cell therapy of PD. The clinical trials of autotransplantation of sympathetic ganglion cells in PD have revealed that the grafts increase the duration of L-DOPA (L-dihydroxy phenyl alanine)-induced beneficial effects, and that the graft-mediated effect is detectable during a follow-up period of at least 1 year postgrafting. In an in vitro analysis of the ability of human sympathetic neurons to release catecholamines, although DA was not detectable under basal conditions, DA levels were significantly increased upon exposure to exogenous L-DOPA. Furthermore, animal experiments with xenografting of human sympathetic ganglionic neurons in the DA-denervated striatum of rats demonstrated that a significant increase in striatal DA levels is noted after systemic L-DOPA treatment, and that the DA levels remain high for longer periods of time in the grafted rats than in control animals with sham surgery. The L-DOPA-induced rise of striatal DA levels was significantly attenuated when given reserpine pretreatment. Thi...Continue Reading

References

Jan 1, 1978·Annual Review of Pharmacology and Toxicology·O Eränkö
Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·J D EricksonB J Hoffman
Sep 22, 1984·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·J Price
Oct 1, 1993·Trends in Neurosciences·G Levi, M Raiteri
Jul 1, 1994·Neurologia Medico-chirurgica·N NakaoS Furukawa
Nov 1, 1994·Trends in Neurosciences·O LindvallM Kokaia
Jul 1, 1995·Journal of the American Academy of Dermatology·C DrottG Claes
Feb 1, 1993·Rinshō shinkeigaku = Clinical neurology·K KuriharaT Hara
Feb 1, 1996·Brain : a Journal of Neurology·G L DeferJ P Nguyen
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·J D EricksonE Weihe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.